While unexpected, previous reports demonstrate that fulvestrant significantly inhibited aromatase [34] and the growth of triple-negative breast cancer cells and tumors which was mediated by decreased ERβ levels [35]. This evidence concerns the gene CYP19A1 and triple-negative breast carcinoma.